Ron J. Mathijssen

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 378 publications

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal: Journal for immunotherapy of cancer

Published: June 15, 2026

Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A DPYD Variant Allele.

Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A DPYD Variant Allele.

Journal: JCO precision oncology

Published: June 08, 2026

Response to the Letter to the Editor Re: "Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC".

Response to the Letter to the Editor Re: "Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC".

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 05, 2026

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

Journal: Pharmacogenomics

Published: April 02, 2026

Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC.

Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 10, 2026

Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.

Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 10, 2026

Neurological complications induced by checkpoint inhibitors: characterising the clinical spectra.

Neurological complications induced by checkpoint inhibitors: characterising the clinical spectra.

Journal: BMJ neurology open

Published: February 09, 2026

Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy.

Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy.

Journal: Cancer immunology research

Published: February 09, 2026

Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.

Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: December 08, 2025

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 02, 2025

Cardiotoxicity of trametinib monotherapy in adults with neurofibromatosis type 1: Results from the TRAIN study.

Cardiotoxicity of trametinib monotherapy in adults with neurofibromatosis type 1: Results from the TRAIN study.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 19, 2025

Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study.

Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study.

Journal: The Lancet regional health. Europe

Published: November 14, 2025

Showing 1-12 of 378

Last Updated: 09/26/2026